Treatment of pulmonary mucormycosis with adjunctive nebulized amphotericin B (MUCONAB trial): Results of an open-label randomized controlled trial.
CAPM
Mucorales
fungal pneumonia
inhaled amphotericin B
invasive mould
zygomycosis
Journal
Mycoses
ISSN: 1439-0507
Titre abrégé: Mycoses
Pays: Germany
ID NLM: 8805008
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
revised:
07
04
2023
received:
13
12
2022
accepted:
11
04
2023
medline:
4
7
2023
pubmed:
25
4
2023
entrez:
24
04
2023
Statut:
ppublish
Résumé
The role of nebulized amphotericin B (NAB) in managing pulmonary mucormycosis (PM) is unknown. In this open-label trial, we randomized PM subjects to receive either intravenous liposomal amphotericin B (control arm, 3-5 mg/kg/day) alone or along with nebulized amphotericin B deoxycholate (NAB, 10 mg twice a day, every alternate day). The primary outcomes were: (1) overall response ('success' [complete or partial response] or 'failure' [stable disease, progressive disease, or death]) at 6 weeks; and (2) the proportion of subjects with adverse events (AE). The key secondary outcome was 90-day mortality. We performed a modified intention-to-treat (mITT) analysis where we included only subjects receiving at least a single dose of NAB. Fifteen and 17 subjects were randomized to the control and NAB arms; two died before the first dose of NAB. Finally, we included 30 subjects (15 in each arm; mean age 49.8 years; 80% men) for the mITT analysis. Diabetes mellitus (n = 27; 16/27 were COVID-19-associated PM) was the most common predisposing factor. The overall treatment success was not significantly different between the control and the NAB arms (71.4% vs. 53.3%; p = .45). Twenty-nine subjects experienced any AE, but none discontinued treatment. The 90-day mortality was not significantly different between the control (28.6%) and NAB arm (53.3%; p = .26). Adjunctive NAB was safe but did not improve overall response at 6 weeks. A different dosing schedule or nebulized liposomal amphotericin B may still need evaluation. More research is needed to explore other treatment options for PM.
Sections du résumé
BACKGROUND
BACKGROUND
The role of nebulized amphotericin B (NAB) in managing pulmonary mucormycosis (PM) is unknown.
METHODS
METHODS
In this open-label trial, we randomized PM subjects to receive either intravenous liposomal amphotericin B (control arm, 3-5 mg/kg/day) alone or along with nebulized amphotericin B deoxycholate (NAB, 10 mg twice a day, every alternate day). The primary outcomes were: (1) overall response ('success' [complete or partial response] or 'failure' [stable disease, progressive disease, or death]) at 6 weeks; and (2) the proportion of subjects with adverse events (AE). The key secondary outcome was 90-day mortality. We performed a modified intention-to-treat (mITT) analysis where we included only subjects receiving at least a single dose of NAB.
RESULTS
RESULTS
Fifteen and 17 subjects were randomized to the control and NAB arms; two died before the first dose of NAB. Finally, we included 30 subjects (15 in each arm; mean age 49.8 years; 80% men) for the mITT analysis. Diabetes mellitus (n = 27; 16/27 were COVID-19-associated PM) was the most common predisposing factor. The overall treatment success was not significantly different between the control and the NAB arms (71.4% vs. 53.3%; p = .45). Twenty-nine subjects experienced any AE, but none discontinued treatment. The 90-day mortality was not significantly different between the control (28.6%) and NAB arm (53.3%; p = .26).
CONCLUSION
CONCLUSIONS
Adjunctive NAB was safe but did not improve overall response at 6 weeks. A different dosing schedule or nebulized liposomal amphotericin B may still need evaluation. More research is needed to explore other treatment options for PM.
Substances chimiques
liposomal amphotericin B
0
Amphotericin B
7XU7A7DROE
Antifungal Agents
0
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-696Informations de copyright
© 2023 Wiley-VCH GmbH.
Références
Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the mycoses study group education and research consortium. Lancet Infect Dis. 2019;19(12):e405-e421.
World Health Organization. WHO fungal priority pathogens list to guide research, development and public health action (Licence: CC BY-NC-SA 3.0 IGO). In: Geneva. 2022.
Patel A, Kaur H, Xess I, et al. A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020;26(7):944.e949-944.e915.
Muthu V, Agarwal R, Dhooria S, et al. Has the mortality from pulmonary mucormycosis changed over time? A systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(4):538-549.
Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother. 2012;67(3):715-722.
Soman R, Gupta N, Shetty A, Rodrigues C. Deferasirox in mucormycosis: hopefully, not defeated. J Antimicrob Chemother. 2012;67(3):783-784.
Funada H, Matsuda T. Pulmonary mucormycosis in a hematology ward. Intern Med. 1996;35(7):540-544.
Allen SD, Sorensen KN, Nejdl MJ, Durrant C, Proffit RT. Prophylactic efficacy of aerosolized liposomal (AmBisome) and non-liposomal (fungizone) amphotericin B in murine pulmonary aspergillosis. J Antimicrob Chemother. 1994;34(6):1001-1013.
Monforte V, Ussetti P, López R, et al. Nebulized liposomal amphotericin B prophylaxis for aspergillus infection in lung transplantation: pharmacokinetics and safety. J Heart Lung Transplant. 2009;28(2):170-175.
Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46(9):1401-1408.
Safdar A, O'Brien S, Kouri IF. Efficacy and feasibility of aerosolized amphotericin B lipid complex therapy in caspofungin breakthrough pulmonary zygomycosis. Bone Marrow Transplant. 2004;34(5):467-468.
Song Y, Zhou M, Gong Q, Guo J. Scedosporium apiospermum and Lichtheimia corymbifera co-infection due to inhalation of biogas in immunocompetent patients: a case series. Infect Drug Resist. 2022;15:6423-6430.
Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity. J Pharm Pharmacol. 2005;57(10):1289-1295.
Mihara T, Kakeya H, Izumikawa K, et al. Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis. J Infect Chemother. 2014;20(2):104-108.
Furco A, Mouchet B, Carbonnelle M, Vallerand H. Pulmonary mucormycosis: benefit of aerosol amphotericin B? Rev mal Respir. 2001;18(3):309-313.
Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med. 2010;152(11):726-732.
Orkin AM, Gill PJ, Ghersi D, et al. Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: the CONSERVE 2021 statement. JAMA. 2021;326(3):257-265.
Donnelly JP, Chen SC, Kauffman CA, et al. Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367-1376.
Muthu V, Agarwal R, Patel A, et al. Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the fungal infection study forum and academy of pulmonary sciences, India. Lancet Infect Dis. 2022;22(9):e240-e253.
Muthu V, Gandra RR, Dhooria S, et al. Role of flexible bronchoscopy in the diagnosis of invasive fungal infections. Mycoses. 2021;64(6):668-677.
Serdar CC, Cihan M, Yücel D, Serdar MA. Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med (Zagreb). 2021;31(1):010502.
Pruthi H, Muthu V, Bhujade H, et al. Pulmonary artery pseudoaneurysm in COVID-19-associated pulmonary Mucormycosis: case series and systematic review of the literature. Mycopathologia. 2022;187(1):31-37.
Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289-1297.
Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760-769.
Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828-837.
Solé A. Invasive fungal infections in lung transplantation: role of aerosolised amphotericin B. Int J Antimicrob Agents. 2008;32(Suppl 2):S161-165.
Palmer SM, Drew RH, Whitehouse JD, et al. Safety of aerosolized amphotericin B lipid complex in lung transplant recipients. Transplantation. 2001;72(3):545-548.
Ram B, Aggarwal AN, Dhooria S, et al. A pilot randomized trial of nebulized amphotericin in patients with allergic bronchopulmonary aspergillosis. J Asthma. 2016;53(5):517-524.
Monforte V, Roman A, Gavaldá J, et al. Nebulized amphotericin B concentration and distribution in the respiratory tract of lung-transplanted patients. Transplantation. 2003;75(9):1571-1574.
Godet C, Couturaud F, Marchand-Adam S, et al. Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial. Eur Respir J. 2022;59(6):2102218.
McGuire FR, Grinnan DC, Robbins M. Mucormycosis of the bronchial anastomosis: a case of successful medical treatment and historic review. J Heart Lung Transplant. 2007;26(8):857-861.
Damaraju V, Agarwal R, Dhooria S, et al. Isolated tracheobronchial mucormycosis: report of a case and systematic review of literature. Mycoses. 2022;66(1):5-12.
Coste A, Conrad A, Porcher R, et al. Influence of underlying conditions on disease presentation and diagnostic strategy during pulmonary mucormycosis: Anational study of 114 cases. Med Mycol. 2022;60:235-237.
Muthu V, Agarwal R, Rudramurthy SM, et al. Multicenter case-control study of COVID-19-associated Mucormycosis outbreak, India. Emerg Infect Dis. 2023;29(1):8-19.
Alexander BD, Winkler TP, Shi S, Dodds Ashley ES, Hickey AJ. In vitro characterization of nebulizer delivery of liposomal amphotericin B aerosols. Pharm Dev Technol. 2011;16(6):577-582.
Kamalaporn H, Leung K, Nagel M, et al. Aerosolized liposomal amphotericin B: a potential prophylaxis of invasive pulmonary aspergillosis in immunocompromised patients. Pediatr Pulmonol. 2014;49(6):574-580.
Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021;64(9):1028-1037.